Results 1 to 10 of about 337 (145)

Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9

Advances in Pharmacological and Pharmaceutical Sciences, 2023
Pexidartinib offered a new therapeutic option for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) who were refractory to surgical treatment and had severe morbidity or functional limitations. Meanwhile, the metabolism of pexidartinib
Yanding Su, Xinyi Wei, Qian Cheng, He Qi, Jianghui Chen, Xiang-Jun Qiu   +5 more
doaj   +4 more sources

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib [PDF]

Cancer Cell International, 2021
Background Acute myeloid leukaemia (AML) is an aggressive blood cancer. In approximately 30% of the cases, driver mutations in the FLT3 gene are identified.
Jingmei Yang, H. Jonathan G. Lindström, Ran Friedman   +2 more
doaj   +4 more sources

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor [PDF]

Case Reports in Orthopedics, 2022
Tenosynovial giant cell tumor (TGCT) is a rare neoplasm of the joint synovium that has a wide clinical spectrum including pain and stiffness in the affected joint, joint swelling, periarticular erosions, and cartilage loss, which can severely impact ...
Nicholas M. Bernthal, R. Lor Randall, Lauren N. Zeitlinger, Erik J. Geiger, John H. Healey   +4 more
doaj   +2 more sources

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial [PDF]

Acta Orthopaedica, 2021
Background and purpose — The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not ...
Michiel Van De Sande, William D Tap, Heather L Gelhorn, Xin Ye, Rebecca M Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J Wagner, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Qiang Wang, Dale Shuster, Hans Gelderblom, John H Healey   +15 more
doaj   +2 more sources

Eco-Friendly, Simple, Fast, and Sensitive UPLC-MS/MS Method for Determination of Pexidartinib in Plasma and Its Application to Metabolic Stability

Molecules, 2022
Pexidartinib is the first drug approved by the U.S. Food and Drug Administration specifically to treat the rare joint tumor tenosynovial giant cell tumor.
Essam Ezzeldin, Muzaffar Iqbal, Yousif A. Asiri, Gamal A. E. Mostafa, Ahmed Y. A. Sayed   +4 more
doaj   +2 more sources

A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer

Advances in Radiation Oncology, 2021
Purpose: This study aimed to evaluate a combination of radiation therapy (RT), androgen deprivation therapy (ADT), and pexidartinib (colony-stimulating factor 1 receptor [CSF1R]) inhibitor in men with intermediate- and high-risk prostate cancer.
Muhammad Hamid, MD, Lance K. Heilbrun, PhD, Jordan Maier, MD, Kiran Devisetty, MD, Irene Connolly, MD, Isaac Kaufman, MD, Kimberlee Dobson, BSME, CCRP, Mackenzie K. Herroon, MA, Daryn Smith, MSc, Sandra Sampson, RN, OCN, Izabela Podgorski, PhD, Elisabeth I. Heath, MD   +11 more
doaj   +2 more sources

Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma

Frontiers in Pharmacology, 2023
There is a crosstalk between Tumor-associated macrophages (TAM) and tumor-infiltrating T cells in tumor environment. TAM could inhibit the activity of cytotoxic T cells; TAM could also regulate the composition of T cells in tumor immune environment.
Wei Zhang, Xi Jiang, Youcheng Zou, Lihua Yuan, Xiaobo Wang   +4 more
doaj   +1 more source

5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate

Molbank, 2023
The dihydrochloride salt of pexidartinib was synthesized and the crystal structure of its dihydrate was determined from single crystal data. The asymmetric unit consists of one formula unit.
Weronika Kozanecka-Okupnik, Klaus Wurst, Sandro Neuner, Sven Nerdinger, Thomas Gelbrich   +4 more
doaj   +1 more source

Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team

Orphanet Journal of Rare Diseases, 2023
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not ...
Colleen McCabe, Hillary Wright, Kathleen Polson, Andrew J. Wagner   +3 more
doaj   +1 more source

Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes

Journal of Neuroinflammation, 2021
Background Alexander disease (AxD) is a rare neurodegenerative disorder that is caused by dominant mutations in the gene encoding glial fibrillary acidic protein (GFAP), an intermediate filament that is primarily expressed by astrocytes.
Michelle M. Boyd, Suzanne J. Litscher, Laura L. Seitz, Albee Messing, Tracy L. Hagemann, Lara S. Collier   +5 more
doaj   +1 more source